OSTX — OS Therapies Incorporated
NYSE MKT · Healthcare · Biotechnology
$1.67
+$0.01 (+0.30%)
OS Therapies Incorporated (OSTX) is a biotechnology company listed on NYSE MKT. It is led by Paul A. Romness M.P.H., based in 115 Pullman Crossing Road, Grasonville, MD, United States, 21638, with about 4 employees. OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Net income was -$6.9M. OSTX currently screens at market cap $74.1M.
Use this OSTX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the OSTX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the OSTX SEC filings page. Lician reads the product cache first so this HTML stays unique to OS Therapies Incorporated even when a live quote feed is slow.
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OSTX Key Statistics
Market Cap
$74.14M
Volume
332,363
Previous Close
$1.55
Day Range
$1.53 – $1.65
EPS
-$0.88
Revenue
$0.00
Net Income
-$8.88M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
4
OSTX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 |
| Net Income | -$8.88M | -$7.79M |
| EPS (Diluted) | -$0.88 | -$1.46 |
Total Assets
$5.54M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$5.53M
Operating Cash Flow
-$7.28M
Free Cash Flow
$0.00
OS Therapies Incorporated Company Information
- Founder, Chairman, President & CEO
- Paul A. Romness M.P.H.
- Headquarters
- 115 Pullman Crossing Road, Grasonville, MD, United States, 21638
- Website
- ostherapies.com
- Phone
- 410-297-7793
- IPO / Founded
- 2024-08-01
- Sector
- Healthcare
- Industry
- Biotechnology